- Home
- HYI vs ESPR Comparison
HYI vs ESPR Comparison
Compare HYI & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYI
- ESPR
- Stock Information
- Founded
- HYI 2010
- ESPR 2008
- Country
- HYI United States
- ESPR United States
- Employees
- HYI N/A
- ESPR N/A
- Industry
- HYI Investment Managers
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- HYI Finance
- ESPR Health Care
- Exchange
- HYI Nasdaq
- ESPR Nasdaq
- Market Cap
- HYI 270.9M
- ESPR 220.0M
- IPO Year
- HYI N/A
- ESPR 2013
- Fundamental
- Price
- HYI $12.03
- ESPR $2.07
- Analyst Decision
- HYI
- ESPR Buy
- Analyst Count
- HYI 0
- ESPR 6
- Target Price
- HYI N/A
- ESPR $6.50
- AVG Volume (30 Days)
- HYI 50.6K
- ESPR 6.6M
- Earning Date
- HYI 01-01-0001
- ESPR 08-05-2025
- Dividend Yield
- HYI 9.59%
- ESPR N/A
- EPS Growth
- HYI N/A
- ESPR N/A
- EPS
- HYI N/A
- ESPR N/A
- Revenue
- HYI N/A
- ESPR $268,125,000.00
- Revenue This Year
- HYI N/A
- ESPR $6.10
- Revenue Next Year
- HYI N/A
- ESPR N/A
- P/E Ratio
- HYI N/A
- ESPR N/A
- Revenue Growth
- HYI N/A
- ESPR N/A
- 52 Week Low
- HYI $10.99
- ESPR $0.69
- 52 Week High
- HYI $12.24
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- HYI 59.57
- ESPR 73.84
- Support Level
- HYI $11.92
- ESPR $1.74
- Resistance Level
- HYI $12.03
- ESPR $1.97
- Average True Range (ATR)
- HYI 0.09
- ESPR 0.17
- MACD
- HYI 0.01
- ESPR 0.04
- Stochastic Oscillator
- HYI 84.09
- ESPR 95.42
About HYI Western Asset High Yield Defined Opportunity Fund Inc.
Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. The fund invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.